Femoral Artery
Death, bleeding lower but stroke higher with radial access PCI vs. femoral access
Use of radial access for PCI has increased greatly in the U.S. over the last decade and is associated with lower risk for mortality, bleeding and nonfatal vascular complications compared with a transfemoral approach, a speaker reported.
PAD intervention via radial access successful, safe in small multicenter cohort
Endovascular treatment of peripheral artery disease via radial access was feasible and safe in a small multicenter cohort, with only one patient requiring conversion to femoral access during, researchers reported.
‘Radial first’ strategy brings benefits to complex, high-risk PCI procedures
Transradial access is now the predominant access site for complex, high-risk PCI procedures and is associated with significantly lower risk for mortality, major bleeding and other adverse events compared with transfemoral access, data show.
FDA approves percutaneous transmural arterial bypass system for treatment of complex PAD
Endologix announced that the FDA has granted approval of its percutaneous transmural arterial bypass system for the treatment of complex peripheral arterial disease.
No major difference in radiation exposure between transradial, transfemoral access in PCI
Data from a meta-analysis show no difference in fluoroscopy time between transradial vs. transfemoral access for PCI; however, diagnostic coronary angiography continues to marginally favor transfemoral access, researchers reported.
Routine ultrasound improved femoral access; did not lower bleeding, vascular complications
BOSTON — Ultrasound-guided femoral access improved first attempt success in coronary procedures but did not reduce the occurrence of major bleeding and vascular complications vs. fluoroscopy alone, a speaker reported.
In common femoral artery lesions, surgery confers better patency vs. endovascular therapy
Compared with endovascular therapy, thromboendarterectomy surgery was associated with better 1-year patency, but longer hospital stays, in patients undergoing revascularization for common femoral artery lesions, researchers reported.
Peripheral DES superior to bare-metal stents for treatment of PAD
A drug-eluting stent outperformed bare-metal stents for treatment of patients with lesions in the superficial femoral and proximal popliteal arteries, according to results of the EMINENT trial presented at VIVA 21.
FDA approves new drug-coated balloon for PAD
Boston Scientific announced the FDA has approved the Ranger drug-coated balloon for the treatment peripheral artery disease in the superficial femoral artery and proximal popliteal artery.
Ascertainment bias could explain paclitaxel mortality signal
LAS VEGAS — It is possible that ascertainment bias and other biases from randomized controlled trials could explain the long-term mortality signal observed in paclitaxel-coated devices, according to a speaker at VIVA 19.